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Abstract: Atherosclerotic occlusive diseases and aneurysms that affect large and medium-sized
arteries outside the cardiac and cerebral circulation are collectively known as peripheral arterial
disease (PAD). With a rise in the rate of aging population worldwide, the number of people diagnosed
with PAD is rapidly increasing. The micronutrient vitamin D is an important steroid hormone that
acts on many crucial cellular mechanisms. Experimental studies suggest that optimal levels of vitamin
D have beneficial effects on the heart and blood vessels; however, high vitamin D concentrations
have been implicated in promoting vascular calcification and arterial stiffness. Observations from
various clinical studies shows that deficiency of vitamin D has been associated with a greater risk of
PAD. Epidemiological studies have often reported an inverse relation between circulating vitamin
D status measured in terms of 25-hydroxivitamin D [25(OH)D] levels and increased cardiovascular
disease risk; however, randomized controlled trials did not show a consistent positive effect of
vitamin D supplementation on cardiovascular disease risk or events. Even though PAD shares all the
major risk factors with cardiovascular diseases, the effect of vitamin D deficiency in PAD is not clear.
Current evidence suggests a strong role of vitamin D in promoting genomic and epigenomic changes.
This review summarises the current literature that supports the notion that vitamin D deficiency
may promote PAD formation. A better understanding of underlying pathological mechanisms
will open up new therapeutic possibilities which is the main unmet need in PAD management.
Furthermore, epigenetic evidence shows that a more holistic approach towards PAD prevention that
incorporates a healthy lifestyle, adequate exercise and optimal nutrition may be more effective in
protecting the genome and maintaining a healthy vasculature.
Keywords: vitamin D; 25(OH)D; peripheral arterial disease; peripheral arterial occlusive disease;
abdominal aortic aneurysm; epigenetics
1. Introduction
Vitamin D is an important micronutrient that is essential for optimal health throughout life.
Recent research suggest that vitamin D may possess a wide range of biological effects beyond its
classically recognized function in bone and mineral homeostasis [1]. Indeed, deficiency of vitamin D
has been associated with increased prevalence of multiple diseases including osteoporosis, a number of
autoimmune diseases, many different cancers and conditions such as hypertension and cardiovascular
diseases (CVDs) [2].
Vitamin D, with D3 (cholecalciferol) and D2 (ergocalciferol) being the most important for human
health, is obtained through two main sources, with UV light-dependent synthesis of cholecalciferol
from cholesterol in the skin being the predominant source of optimal vitamin D levels (Sunlight is the
major natural source of vitamin D). To a lesser degree, vitamin D may also be obtained through diet
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(dairy products, eggs or fatty fish being examples) or supplements as vitamin D3 or vitamin D2 [2]
(Figure 1). As vitamin D is naturally found in a limited range of foods, fortified foods often provide
supplementation required for maintaining optimal health.
Figure 1. Schematic illustration vitamin D synthesis pathway and signalling mechanisms relevant
to PAD formation. The main forms of vitamin D in nature are vitamin D3 (cholecalciferol) that is
synthesized in the skin of animals and humans in response to sunlight and obtained through diet.
The vitamin D3 travels in the circulation bound to DBP. Vitamin D must undergo several hydroxylation
steps to become an active metabolite. The synthetic pathway involves 25- and 1-alpha-hydroxylation of
vitamin D3 and D2, in the liver and kidney, respectively. The first hydroxylation occurs in the liver
resulting in the formation of 25(OH)D3 or calcidiol and the second hydroxylation occurs mainly within
the kidneys and intestinal epithelial cells and immune cells and generates the most biologically active
hormonal form of vitamin D: 1, 25(OH)2D, or calcitriol. The biologically active form of vitamin D3 is
involved in the regulation of numerous cell cycle regulatory mechanisms protecting the vasculature
from pathological conditions. Abbreviations: Ca2+, calcium; DBP, vitamin D binding protein; PAD,
peripheral arterial disease; Vit D3, vitamin D3.
Deficiency of vitamin D has been previously reported to be common worldwide [3,4] with
approximately 50% of the global population exhibiting lower circulating levels of vitamin D [5–7].
A systematic review by Hilger J, et al. (assessing 195 studies published in 1990–2011 in 44 countries,
with more than 168,000 participants) highlights that people residing in North America had higher
circulating vitamin D levels compared to Europe, Middle East or Africa, furthermore a difference in
circulating levels were reported between the European countries [3]. Given that vitamin D synthesis is
mainly through sunlight, factors such as the skin tone, availability of sunlight, etc. may account for
these differences in vitamin D levels.
In recent research, inadequate vitamin D status has been linked to non-skeletal major disease
such as CVD [8]. Of particular interest to this review, is the emerging concept of the association of
vitamin D in cardiovascular health and the contribution of its deficiency towards the development
and progression of peripheral arterial disease (PAD). While patients with PAD often have a sedentary
lifestyle with limited exposure to sunlight. Age may also be a factor, with the prevalence of PAD being
greater in the elderly. Interestingly, the capacity of UV-mediated vitamin D synthesis was previously
reported to be reduced in aged skin, with an associated reduced expression of the vitamin D receptor
in aged human muscle [9]. As such, dietary supplementation of vitamin D for such patients may be
beneficial towards reducing the risk of CVD/PAD, as well as improving patient outcomes. Hence, it is
of interest to know the pattern of PAD prevalence and the link with vitamin D status if any, to inform
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public health policy development to reduce risk for potential health consequences of an inadequate
vitamin D status. Furthermore, it is vital to understand whether the association of vitamin D and PAD
is causative or is reverse causality. However, the presence of receptors for vitamin D in the vascular
wall suggests that this micronutrient might play a role in the pathogenesis of arterial diseases [10].
In this review, the role of vitamin D in maintaining arterial health is assessed and the effect of vitamin
deficiency on the genome and beyond is explored, with special relevance to PAD.
2. Peripheral Arterial Disease (PAD)
Atherosclerotic occlusive conditions and aortic aneurysms that affect large and medium-sized
arteries outside the cardiac and cerebral circulation are collectively known as PAD [11].
Specifically, PAD comprises of the pathological changes occurring in the abdominal aorta, iliac and
lower-extremity arteries. Peripheral arterial occlusive disease (PAOD) or lower extremity arterial
disease is an athero-thrombotic disease leading to stenosis or occlusion of the leg arteries, and eventual
death of tissue due to continued ischemia. Abdominal aortic aneurysms (AAA) are degenerative
diseases characterised by extensive inflammation and extracellular matrix (ECM) remodelling and
eventual destruction of medial layer of aorta resulting in its rupture. Patho-physiologically, both PAOD
and AAA are multifactorial conditions with multi-phase complications. A number of risk factors are
currently known, several of these are known to cause alterations to the genome and epigenome. It is
evident that there is an urgent need of new and better therapies and to investigate other factors that
are associated with the disease’s presence and progression. A detailed description of the pathology
of PAD is beyond the scope of this review and readers are advised to refer to the previous excellent
reviews on this topic [12,13].
2.1. Vitamin D Status and PAOD Formation
PAOD occurs due to an impediment of the blood flow to the lower extremities and manifests as
intermittent claudication (IC) or leg pain during walking and critical limb ischemia (CLI) where there
is tissue loss [14]. In primary care, diagnosis of PAOD is performed by measuring the ankle-brachial
pressure index (ABPI) with a score <0.9. More than 200 million globally has been estimated to be
affected by PAOD [15,16]. Given the trend in the aging population, the prevalence of PAD and
lower limb PAOD has been projected to rise in forthcoming years [16–18] and is expected that the
PAOD prevalence will double by 2040 [19]. A recent meta-analysis highlighted that PAOD poses
as a significant global threat in both high-income and low-to-middle income countries, suggesting
that the condition is prevalent worldwide [16]. Even in developed countries, PAOD continues to be
underreported and undermanaged [20]. PAOD patients are at approximately three times higher risk of
cardiovascular and all-cause mortality despite the currently available effective medical therapy [21].
This results in poor outcome for the patient, with chronic claudication pain, ischemic ulcerations,
repeated hospitalizations, revascularizations, limb necrosis and eventual limb loss. As a consequence,
these problems result in an overall poor quality of life and a high rate of depression among PAOD
patients [22]. Hence, better and effective treatments are urgently required to reduce the high risk of
lower limb and cardiovascular events in this population.
Current studies strongly suggest a correlation between reduced circulating vitamin D levels and
presence of PAOD [23–31], although some epidemiological studies have shown no correlation [32–34].
Table 1 shows cross-sectional studies investigating vitamin D levels in circulation in PAOD patients.
It should be noted that the threshold for low vitamin D or hypovitaminosis defined by 25(OH)D levels
were not similar in these studies, with low vitamin D levels defined in the range from <17.8 ng/mL
to <30 ng/mL. This could be a reason for the difference in the correlation shown between the studies.
Furthermore, the geographical location of the patient population tested varied between the studies,
leading to other confounding factors, which could potentially lead to the change in vitamin D levels.
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Table 1. Cross-sectional studies investigating vitamin D circulating levels in peripheral arterial occlusive
disease (PAOD) patients.
Studies Type of Study Country Main Findings Refs
Rapson IR, et al. 2017 Prospective USA, ARIC studycohort
Deficiency of 25(OH)D was associated with
increased risk of PAOD in black and white
participants
[23]
Liew JY, et al. 2015 Cross-sectional(case-control) Australia
No significant difference 25(OH)D levels
was detected between PAOD patients (only
IC) and control
[32]
Veronese N, et al. 2015 Prospective Italy, communitydwelling men
Baseline hypovitaminosis D (<24 nmol/L)
did not predict the onset of PAOD over
a 4.4-year follow-up in elderly people
[33]
Amer M, et al. 2014 Retrospective USA
Elevated serum 25(OH)D concentration
was associated with significant increase in
ABPI in asymptomatic adults without
PAOD
[24]
Stricker H, et al. 2012 Double-blind,placebo-controlled
Caucasian,
Switzerland
PAOD patients had low 25(OH)D levels
(<30 ng/mL) [25]
McDermott MM, et al.
2012
Cross-sectional
(case-control) USA
No significant difference 25(OH)D levels
was detected between PAOD patients (only
IC) and control
[34]
Gaddipati VC, et al. 2011 Cross-sectional USA
Deficiency of 25(OH)D (<20 ng/mL) was
associated with an increased amputation
risk in veterans with PAOD
[26]
Zagura M, et al. 2011 Cross-sectional(case-control) Estonia
PAOD patients had lower 25(OH)D
compared to controls [27]
Melamed ML, et al. 2008 Cross-sectional(case-control)
USA, nationally
representative
adults >20years of
age
Lower serum 25(OH)D levels are associated
with a higher prevalence of PAOD [28]
Reis JP, et al. 2008 Cross-sectional USA
After adjustment for 25(OH)D levels, odds
for PAOD were reduced from 2.11 (95% CI:
1.55, 2.87) to 1.33 (95% CI: 0.84, 2.10) in
black compared with white participants
[29]
Fahrleitner-Pammer, et al.
2005
Cross-sectional
(case-control) Austria
Patients with CLI symptoms had lower
25(OH)D compared to both IC and controls [30]
Fahrleitner A, et al. 2002 Cross-sectional(case-control) Austria
Patients with CLI symptoms had lower
25(OH)D compared to both IC and controls [31]
Abbreviations: ABPI, ankle brachial plexus index; ARIC, Atherosclerosis Risk In Communities; CLI, critical limb
ischemia; IC, intermittent claudication; PAOD, peripheral arterial occlusive disease.
Data from the National Health and Nutrition Examination Survey (NHANES, 4864 participants,
1999–2002) shows that the patients with PAOD had lower plasma levels of vitamin D [35]. Reports
from the Atherosclerosis Risk In Communities (ARIC) study shows that lower levels of 25(OH)D
was associated with 30% increased risk of PAOD in participants regardless of their ethnicity [23].
Moreover, in another cross-sectional analysis (NHANES, 2001–2004), an 80% higher prevalence of
PAOD was reported in participants in the lowest quartile of 25(OH)D compared to the participants
in the highest quartile [28]. In a recently performed a meta-analysis on six observational studies,
we showed that PAOD patients (n = 1217) had lower 25(OH)D compared to non-PAOD participants
(n = 5201) [36]. Interestingly, the study also demonstrated that patients with advanced PAOD symptoms
of CLI had even lower circulating levels of 25(OH)D when compared with PAOD patients that had IC
symptoms [36]. This is corroborated by the observation that patients with PAOD shows progressive
functional decline [10] and low vitamin D status was associated with lower ABPI and a faster decline
of functional performance [37].
As indicated by several studies in humans and in animals, aging results in a decline in the ability
of the kidney to synthesize 1,25(OH)2D3 [38]. Furthermore, PAD patients experience severe debilitating
lower limb symptoms which includes, IC, rest-pain, arterial ulcers and gangrene, which severely
limit their physical activity [39]. The reduced ability of the kidney to synthesis 1,25(OH)2D3 and
probably the limited exposure to sun which results in the lack of efficient cutaneous production could
result in the reduced vitamin D levels seen in the PAD patients. Furthermore, as seen in the CVDs,
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the reduced vitamin D levels reported in various studies could also be due to different confounding
factors including environment, age, sex, socio-economic and nutritional status.
2.2. Vitamin D Status and AAA Formation
Abdominal aortic aneurysm (AAA) is pathologically characterised by progressive degeneration of
the arterial wall structure by chronic inflammation and ECM remodelling which leads to irreversible
dilatation and eventual rupture resulting in death [13,40]. AAA affects 4–8% of men and 1.5% of
women above the age of 60 years and usually remains asymptomatic until rupture [41]. AAA rupture
is a medical emergency with a high mortality rate (80–90%) and majority of the deaths occurring before
reaching the hospital. Approximately 20 million people are estimated to have AAA [18,42] and given
the trend in the aging population, the prevalence of AAA has been projected to rise in forthcoming
years [16–18].
An interesting population-based cohort study from northern Sweden, showed seasonal
hypovitaminosis in the population [43]. A higher prevalence of AAA was reported in the adults and the
reported incidence of AAA repair was also higher in the northern region where sunlight is scarce [43,44]
showing a possible correlation between vitamin D status and AAA formation. Deficiency of vitamin
D was shown to be an independent risk factor associated with thoracic aortic dilatation [45] and an
inverse relationship between vitamin D levels and AAA development has also been established [46–48].
In an observational study of 4233 community-dwelling men (age range 70–88 years), who participated
in a randomised controlled trial of screening for AAA, low vitamin D status in older men was
associated with the presence of larger AAA [46]. A graded inverse relationship was observed between
circulating 25(OH)D concentrations and AAA diameter. A recent pooled analysis of three case-control
studies demonstrated significantly lower circulating 25(OH)D levels in patients with AAA than
subjects without AAA [49]. A study utilised redox proteomic approach to investigate total and
specific protein carbonylation and protein-bound 4-hydroxy-2-nonenal (HNE) in the serum of AAA
patients compared with age-matched controls [50]. The results show specific carbonylation of three
serum proteins, which included vitamin D-binding protein (DBP), serum retinol-binding protein and
fibrinogen α-chain HNE, suggesting the importance of adequate vitamin D levels in AAA formation.
A recent clinical evaluation study on small number of AAA patients (n = 11) showed that selective
activation of vitamin D receptor (VDR) by paricalcitol (1µg daily, 24–weeks before open AAA repair)
interferes with calcineurin-mediated inflammation in AAA [51]. Paricalcitol is a VDR agonist and the
mechanism of action was shown to be anti-inflammatory action by reduction in T cell activation. To
date, there are no large-scale clinical trials assessing the link between vitamin D supplementation and
AAA, therefore clear evidence of a treatment effect is lacking.
Contradictory studies also exist showing that confounding factors could play a role in determining
the association between vitamin D status using currently available biomarkers (vitamin D metabolic
markers) and AAA presence. For example, a recent prospective epidemiologic study examined the
association between serum 25(OH)D concentrations and incidence of AAA in the ARIC cohort [52].
However, in this large prospective cohort (12,770 participants), there was no association between
25(OH)D concentrations and risk of AAA presence. The DBP is the major plasma carrier protein of
vitamin D and used as a biomarker of vitamin D metabolism. However, the presence of DBP and its use
as a reliable biomarker in AAA is contradictory. A previous proteomic study showed that DBP levels
positively correlated with the size and expansion of AAA [53], however another proteomic analysis
of plasma proteome of patients undergoing AAA repair showed a negative correlation between the
DBP and AAA presence [41]. It should also be noted that in most of these studies, the biomarkers
are measured as a one-off measurement and may not be possibly coinciding with the natural history
of AAA [52]. Furthermore, recently it was highlighted that unbound free-25(OH)D might be a better
reliable biomarker of vitamin D status [54]. These observations suggest that further studies are required
to understand which vitamin D metabolite is optimal in ascertaining vitamin D status [54].
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Vitamin D3 seems to act on a range of cellular and molecular mechanisms important to the
pathogenesis of AAA [55] (Figure 2). Evidence from preclinical studies shows that calcitriol
treatment significantly attenuates dissecting AAA formation [56]. Oral treatment with calcitriol
reduced angiotensin II (AngII)-induced dissecting AAA formation in apolipoprotein E deficient
(ApoE-/-) mice with marked increase in VDR-retinoid X receptor (RXR)-α interaction in the aortas
of calcitriol-treated mice. Calcitriol-co-treated mice also exhibited reduced macrophage infiltration,
matrix metalloproteinase (MMP) and chemokine expression in the suprarenal aortic walls, which seems
to be mediated specifically through activation of VDR–RXR-α interactions [56]. Increasing evidence
suggests that vitamin D3 is a potent endogenous regulator of the renin–angiotensin-aldosterone-system
(RAAS) [57–59]. Accordingly, VDR-deficient mice display high renin and AngII levels and develop
hypertension [57]. In addition to regulating the components involved in synthesizing AngII,
calcitriol also alters the expression of AngII, AT1 receptors in several target tissues [60,61]. In vitro studies
also showed that VDR activation by calcitriol in human endothelial cells (ECs) inhibited AngII-induced
leukocyte-EC interactions, morphogenesis, and production of endothelial pro-inflammatory and
angiogenic chemokines through VDR-RXR interactions, and knockdown of VDR or RXR abolished the
inhibitory effects of calcitriol [56].
Figure 2. Schematic illustration vitamin D canonical signalling pathway and its role on mechanisms
relevant to PAD formation. The biologically active form of vitamin D3 is 1,25(OH)2D3, is a ligand for
a nuclear transcription factor VDR. VDR is present in most cell types and once the VDR is bound with
1,25(OH)2D3, then it translocates to the nucleus. VDR has a binding site that recognises the target
sequence in the genome. VDR binds to genomic DNA after it dimerizes with RXR. The genomic region
that binds to VDR and 1,25(OH)2D3 is restricted by CTCF protein, which defines the TAD. CTCF is
a transcription factor which is often found near the TSS on the chromatin. For 1,25(OH)2D3 to initiate
transcription, the target gene should have its TSS and at least one VDR binding site at a location within
the same chromatin. The vitamin D target genes that fall within the TAD region of a chromatin will
undergo gene expression. Genes containing a specific promoter region known as VDRE will allow
the binding of VDR-RXR dimers to the VDRE region and recruit transcriptional machinery including
transcription factors and RNA polymerase II. Abbreviations: CTCF, CCCTC-binding factor; PAD,
peripheral arterial disease; RXR, Retinoid X Receptor; TAD, Topologically Associated Domain; TSS,
Transcription Start Site; VDR, Vitamin D Receptor; VDRE, Vitamin D Response Elements.
3. Vitamin D Status and Mechanisms Relevant in PAD Formation
Vitamin D has a range of biological functions and affect many crucial mechanisms and cell
types that maintain a healthy vasculature (Figure 3). Insufficient levels of vitamin D may affect the
vasculature via the classic mechanism of promoting changes in the calcium-phosphate metabolism,
or via effects on the RAAS [57]. The RAAS is an important endocrine system which controls peripheral
vascular resistance, vascular tone and volume homeostasis and the major vascular protective effect of
vitamin D is attributed to also its ability to upregulate nitric oxide (NO) which regulates RAAS [62,63].
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Figure 3. Schematic illustration summarising the effect of vitamin D on various resident cells and
its role in modulating the molecular mechanism involved in PAD formation. Vitamin D has been
proposed to be involved in the regulation of many cell types involved in PAD formation, mainly the
residential vascular cells such as endothelial cells, vascular smooth muscle cells, firboblasts and also
infiltrating and/or circulating immune cells. Vitamin D has shown to be potent growth modulator,
protector of endothelial function and inflammatory response mediator on the resident vascular cells
playing a crucial role in atherogenesis. Optimal vitamin D status is crucial for the functioning of the
resident cells and thus it plays a major protective effect in vascular wall promoting matrix integrity.
Abbreviations: Ca2+, calcium; DBP, vitamin D binding protein; PAD, peripheral arterial disease; Vit. D3,
vitamin D3.
3.1. Aortic Cells and Dysfunction
Vitamin D has been proposed to be involved in the regulation of many cell types involved in
PAD formation, such as infiltrating/circulating immune cells, as well as residential vascular cells, such
as ECs and vascular smooth muscle cells (VSMCs) [64,65] (Figure 3). Indeed, the presence of VDR
on VSMCs and ECs suggests that Vitamin D may have a direct role in the regulation of vascular
function [66]. In vitro, 1,25(OH)2D3 has been shown to be a potent modulator of the growth of
VSMC [67], imparts an inflammatory effect upon ECs [68] playing a role in accelerated proliferation
increased carotid intima-media thickness (IMT). Active form of vitamin D, calcitriol has previously
shown to promote proliferation in VSMCs [69] and promote upregulation of endothelin and NO in
cultured ECs [70]. Both EC and VSMCs are also able to locally produce calcitriol from calcidiol [71].
Both cell types are shown to downregulate the production of atherogenic molecules when exposed to
vitamin D [72], suggesting that optimal vitamin D status is crucial for the functioning of these cells.
As the major vascular protective role of vitamin D is NO upregulation which directly affects
the ECs, it can be assumed that ECs will be the first responders of any alteration in vitamin D
status. Vitamin D has shown to reduce endoplasmic reticulum stress and oxidative stress in EC
thereby reducing atherosclerosis [73]. Attenuated NO production in rat aortic ECs was restored by
12 h of calcitrol treatment [61] and the NO production was shown to occur via the interaction with
VDR [74] suggesting a direct role of vitamin D in protecting the vascular endothelium from dysfunction.
In vivo testing of calcitrol in rats showed an increase in the levels of endothelin-1 in plasma and
tissue NO production as well as an upregulation of endothelial NO synthase enzyme (eNOS) content
in aorta. Mice with deficiency of VDR (Vdr-/-) have increased levels of renin and consequently of
AngII, resulting in hypertension and cardiac hypertrophy, lipid metabolism, cellular stress response,
and changes in the vascular function [57]. The lack of Vdr signalling results in chronically lower NO
bioavailability due to reduced expression of eNOS enzyme, and these effects are independent of changes
in the RAAS [75]. Vdr null mice display a pro-thrombotic state that was associated with a decrease
in antithrombin and thrombomodulin [76]. EC specific deletion of Vdr in mice results in endothelial
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dysfunction evidenced by impaired blood vessel relaxation, an effect that was associated with reduced
eNOS expression [77]. Calcitriol has shown to attenuate human glycated albumin-induced IL-6 and
IL-8 production in fibroblasts [78], indicating a potential protective effect in AAA where fibroblast
plays crucial role in maintaining matrix integrity.
3.2. Atherosclerosis
Atherosclerosis is the primary cause of PAD and is characterized by focal lumen-narrowing
by atheromatous plaques in the intima of large and medium-sized vessels. Patients with severe
atherosclerosis in the coronary arteries have a significantly lower 25(OH)D level compared to patients
without significant lesions [79] suggesting a possible similar role in PAD. Vitamin D has been shown to
promote the expression of anti-atherogenic monocyte/macrophage subtypes and downregulate the
production of various molecules involved in atherogenesis by the ECs and VSMCs [72] suggesting
a role of adequate levels of vitamin D in protecting vasculature from the formation and progression of
atherosclerosis [62].
Calcitriol has been shown to prevent atherosclerotic plaque destabilization in diabetic individuals
by inhibiting the transformation of macrophages to foam cells [80] and the suppressive effect on
MMP activity [81]. It should be noted that in macrophages from diabetic individuals, the activation
of VDR signalling directly leads to a reduction in the uptake of modified low-density lipoprotein
cholesterol, thereby preventing foam cell formation. Vitamin-deficient participants had larger aortic
IMT, a predictive marker for subclinical atherosclerosis, compared to those with normal vitamin D
levels [82]. Vitamin D deficiency was highly prevalent in patients with occlusive and aneurysmatic
arterial disease, independent of traditional CVD risk factors, and showed a strong association
with the severity of the arterial disease and atherosclerotic markers such as carotid artery IMT,
ABPI and high-sensitive CRP [10]. Deficiency of vitamin D has been identified as a potential risk
factor for PAD, if 25(OH)D3 levels decrease below 10 ng/mL (OR, 1.35; 95% CI, 1.15–1.59) [28,83].
Interestingly, low circulating 25(OH)D has also been associated with accumulation of unfavourable
blood lipid profiles [84], another common factor among PAD patients [85].
Vitamin D has been shown to be effective at inhibiting atherosclerosis lesion formation in animal
models [62,86,87]. Oral administration of calcitriol decreases atherosclerosis in ApoE−/− mice by
decreasing macrophage accumulation and inducing T regulatory cells (Tregs) and immature dendritic
cells with tolerogenic functions [86]. Vitamin D supplementation protected hypercholesterolemic
Yucatan microswine against atherosclerosis by controlling cholesterol efflux and macrophage
polarization [87]. Additionally, 1,25(OH)2D3 was shown to increase the expression of liver X receptors,
ATP-binding membrane cassette transporter A1, and ATP-binding membrane cassette transporter G1
and promoted cholesterol efflux in THP-1 macrophage-derived foam cells. Collectively, the findings
appear to reinforce the notion that low vitamin D could potentially contribute to PAD pathogenesis
through mechanisms that are directly and indirectly related to thrombo-atherogenesis lending support
to the observed athero-occlusive condition in PAD patients.
3.3. Inflammation
Inflammatory cells such as monocyte/macrophage plays major role in atherosclerosis formation
and vitamin D has been shown to promote the expression of anti-atherogenic monocyte/macrophage
subtypes [72]. Vitamin D has an important role in the immune system as it has been shown to
have immune-modulating anti-inflammatory activities [88] and its deficiency has been implicated in
systemic and vascular inflammation [89,90]. 1,25(OH)2D3 regulates both innate and adaptive immunity
in opposite directions, i.e.; it promotes the innate immune response and inhibits the adaptive immune
response [91]. The immunosuppressive effect of 1,25(OH)2D3 is mediated through a decrease in
inflammatory cytokines including interleukin (IL)-2 and interferon (IFN)-γ [92]. Immunomodulatory
property of 1,25(OH)2D3 has also been shown to be mediated through an enhancement of Tregs and
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through the induction of transcription factor Foxp3, which is crucial in the development and function
of Tregs [1].
Clinical studies suggest that low levels of vitamin D3 are associated with inflammation and the
consequent endothelial dysfunction [93]. An observational study (Irish adults aged >60 years, n = 957)
showed that low circulating 25(OH)D was associated with increased inflammation, including elevated
IL-6 and hs-CRP, paralleled by reduced levels of anti-inflammatory cytokine IL-10 [94]. Low circulating
25(OH)D has previously been associated with blood lipid profiles [84], and macrophages harvested
from obese, diabetic and hypertensive patients showed that vitamin D limited foam cell formation
and improved high density lipoprotein transport [80] suggesting that the protective effect might be
mediated through the action on macrophages.
1,25(OH)2D3 interferes with the maturation of dendritic cells and maintains the dendritic cells
in a semi-mature state and in vivo exposure of mouse dendritic cells to 1,25(OH)2D3 results in
restoring their functional migratory capacity and decrease the proliferation of activated T cells [95].
Administration of calcitriol induces two major immune cells induced in atherosclerotic lesions namely,
Tregs and immature dendritic cells via the intestinal immune system, resulting in mutually suppressing
pathogenic immune processes that play a pivotal role in the progression of atherosclerosis [86]. In ApoE-/-
mice, supplementation of calcitriol was shown to attenuate atherosclerosis formation by increasing Treg
subsets and decreasing differentiation of dendritic cells or by activation of VDR [86,96]. Calcitriol has
been shown to be anti-atherosclerotic in ApoE-/- mice by attenuating macrophage accumulation,
promoting functions of Tregs and dendritic cells [86] and in swine by promoting cholesterol efflux and
macrophage polarization [87]. Calcitriol has been shown to have anti-inflammatory properties and the
inhibitory effect was via supressing the production of IL-6 and tumour necrosis factor (TNF)-α [97].
Evidence clearly shows a major anti-inflammatory role of vitamin D, however, understanding of
mechanisms by which vitamin D deficiency alters pathological events in PAD remains elusive.
3.4. Arterial Stiffness and Calcification
Vascular calcification is a pathology characteristically observed in advanced age and localised
intimal calcification is a feature of atherosclerosis. Extensive medial calcification is a common presenting
feature of PAD and is visible even on plain X-ray [98]. Medial arterial calcification is associated with
increased pulse pressure and arterial stiffness [99]. Vascular stiffness is an established predictor of
cardiovascular morbidity and mortality and deficiency of vitamin D has also been associated with
vascular stiffness [90]. An inverse association has been shown between 25(OH)D3 and parameters of
endothelial dysfunction [93,100] and arterial stiffness [93], suggesting a role for hypovitaminosis in
PAD formation. It is interesting to note that arterial stiffness was generally assessed by brachial artery
flow-mediated dilation [93], which is a common assessment used to determine the effect of physical
activity in PAD patients.
A randomised control trial involving a small number of black youth (n = 49), showed that
daily supplementation of vitamin D (2000 IU) improved arterial stiffness [101]. A randomised
placebo-controlled trial in non-diabetic chronic kidney disease (CKD) patients with low vitamin D
levels who were supplemented with oral vitamin D3, showed a significant improvement in brachial
artery flow-mediated dilation indicating a protective effect of vitamin D on endothelial/vascular
function [102]. Aortic stiffness and decreased vessel compliance has been reported in hypertensive
patients and a significant antihypertensive effect of vitamin D was reported in hypertensive patients
deficient in vitamin D [103]. Supplementation with vitamin D also decreased arterial stiffness as
indicated by decreased pulse wave velocity showing the vascular protective effect of optimal vitamin
D levels. However, preclinical studies show that caution must be employed when administering
vitamin D supplementation, as lower levels of paricalcitol administration was protective against aortic
calcification, however at higher dose it induces aortic calcification [104].
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3.5. Vitamin D Status and Angiogenesis
ECs are the primary constituents of new vessel formation which occurs by a process called
angiogenesis. A variety of endothelial functions are required for efficient angiogenesis to occur. PAOD
is characterised by reduced angiogenesis due to continued ischemia to distal tissues. Cell proliferation
is an important step in angiogenesis and it is shown previously that vitamin D3 influences cell cycle and
proliferation through a vascular endothelial growth factor (VEGF)-mediated pathway [69,105]. In vitro
evidence shows a significant effect of vitamin D3 on angiogenic potential of endothelial progenitor
cells (EPCs) [105]. A significantly higher proliferative rate and increased formation of the whole
length of capillary-like structures on matrigel was observed when EPCs were treated with vitamin D3.
The increase capillary-formation observed after vitamin D3 treatment in EPCs in comparison to controls
could be mediated by the increased expression of VEGF that is known to stimulate the proliferation,
migration and differentiation of ECs. Vitamin D has been shown to regulate NO production and
endothelin-1 in EC in vitro [70], which also stimulates angiogenesis.
The effect of vitamin D on angiogenesis is ambiguous. Preclinical animal model studies show
conflicting data on the effect of vitamin D status on angiogenesis. Animal model studies in kidney
fibrosis model in mice showed that vitamin D upregulates expression of multiple genes including
endothelin-1 and VEGF, thereby limiting vascular remodelling and ischemia [106]. Majority of the
anti-angiogenic information regarding vitamin D is derived from cancer studies and vitamin D was
shown to exhibit anti-cancer effects by reducing vascularity [107]. Calcitriol negatively influences
angiogenesis by inhibition of VEGF and induction of apoptosis in epithelial cells (melanoma) [108].
ECs derived from tumours from Vdr-/- mice showed that vitamin D decreased the proliferation of ECs
and loss of VDR lead to an upregulation in the levels of angiogenic factors such as VEGF, HIF-1α,
angiopoietin-1 and platelet-derived growth factor [109]. Previous studies also showed that 1,25(OH)2D3
lead to significant attenuation of retinal neovascularization in a mouse model of oxygen-induced
ischemic retinopathy [110] and during retinal vascular development [111]. Calcitriol promotes
pro-angiogenic molecules including VEGF and decreased angiogenin and HIF-1α expression in
keratinocytes in a diabetic foot ulcer model and in ECs and keratinocytes in vitro [112]. Vitamin D
intervention does not improve vascular regeneration in diet-induced obese male mice with peripheral
ischemia [113]. The study shows that recovery of hind limb use in diet-induced obese mice
following acute ischemic injury was improved in niacin-treated mice compared to vitamin D-treated
mice suggesting limited benefit of vitamin D supplementation vascular regenerative processes.
Well-designed preclinical studies using patient relevant models are necessary to identify the effect of
vitamin D supplementation in PAD formation.
4. Vitamin D and the Genome
Physiologically, vitamin D is sourced from cutaneous radiation by ultraviolet B from the sun and
dietary intake [7,114] (Figure 1). The initial, and most crucial step during vitamin D bio-activation is
hepatic hydroxylation to 25(OH)D by the enzyme Cytochrome P450 Family 2-Subfamily R Member 1
(CYP27A1) [115–117]. Liver mitochondrial and microsomal 25-hydroxylases (25-OHases), encoded by
CYP27A1, carry out the first hydroxylation of vitamin D to form 25(OH)D3. The main circulating form
of vitamin D is 25(OH)D and assay for this metabolite are recommended for assessment of vitamin D
status [6]. 25(OH)D circulates bound to DBP, accounting for both endogenous and exogenous sources.
In addition to its transportation role, DBP also regulates the uptake of 25(OH)D by target cells [114].
Vitamin D bio-activation occurs mainly during renal hydroxylation of the circulating 25(OH)D to
1α,25-dihydroxyvitamin [1α,25(OH)2D] which is catalyzed by the enzyme CYP27B1 [1].
Recent advances in molecular techniques has facilitated elucidation of vitamin D genomic
effects [118]. It has been shown that in order for vitamin D to mediate gene transcription, 1α,25-(OH)2D3
has to bind to the cytosolic/nuclear receptor, a member of the steroid/thyroid hormone receptor
superfamily named VDR. The VDR is a member of the nuclear receptor family that regulates gene
transcription by forming a hetero-dimer with RXR, which binds to vitamin D-response elements (VDRE)
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in the promoter regions of target genes [119] (Figure 2). This interaction is facilitated by a heterodimer
formation with the RXR of the steroid receptor family members; which then communicates directly
with DNA sequences located within regulatory regions of target genes (Figure 2). Formation of this
complex facilitates exposure of unique binding sites on the surface of both the VDR and RXR resulting
in recruitment of additional multi-protein co-regulatory complexes and this subsequently leads to either
activation or inactivation of target genes. The gene product is transcribed in response to a positive or
negative VDREs located in the promoters, enhancers or suppressors of the genes. The direct modulation
of transcription by VDR ligands occurs if there is at least one activated VDR close to the transcription
start site (TSS) of the specific primary target gene achieved through site directed (site-specific) binding
to DNA (Figure 2). For example, the VDRE complex is located in Osteopontin gene (SSP1) and the
CYP24A1 gene. The active vitamin D when bound to VDR, regulates VDR expression through VDREs
in its own enhancers, there by auto-regulating VDR.
The non-genomic pathways are activated via a putative membrane VDR and might be responsible
for rapid effects of vitamin D. The VDR gene is located on chromosome 12q12-q14 in humans.
Several frequent polymorphisms are also found in the VDR gene and were reported to be associated with
a variety of phenotypes in many populations. However, to date the status of VDR gene polymorphisms
was not assessed in PAD population. Interestingly, expression of VDRs and 1α-hydroxylase (1α-OHases)
by the crucial cell types in the vasculature, including ECs, VSMCs and immune cells currently
support the evidence that these cells have the ability to synthesize 1,25(OH)2D from circulating
25(OH)D [1,120]. Locally synthesised 1α,25-(OH)2D then mediates both autocrine and paracrine effects
in these cells. The non-genomic effect of vitamin D also include regulation pathways of calcium and
phosphate homeostasis, activating several kinases, which play a role in modulating various signalling
pathways [121].
The binding of VDR, a nuclear transcription factor, to 1,25(OH)2D elicits physiological regulation
of gene transcription [122] (Figure 2). The vitamin D endocrine system regulate approximately 3% of
the human genome [123]. Genome wide analysis of human samples have enabled molecular profiling
of vitamin D levels and the response to vitamin D3 supplementation [124]. A study of peripheral
blood mononuclear cells (PBMNCs) and adipose tissue biopsies from elderly, pre-diabetic individuals,
who were supplemented with vitamin D3 for more than 5 months (n = 71) showed the expression
levels of multiple genes to be directly correlating with alteration in 25(OH)D3 levels. This shows
that individuals can be classified as responders and non-responders based on molecular profiling to
understand whether they will be benefitted prior to supplementation with vitamin D3 [124].
5. Vitamin D and the Epigenome
The epigenome is a crucial layer of information, which regulates and decides on the part of the
genome which are accessible and thereby regulate which regions are active. The epigenome is the
chromatin state of a cell, which encompasses the genomic location of DNA and histone modifications,
transcription factor binding sites, and the 3-dimensional structure of the DNA. The DNA is packaged
within the eukaryotic cell leading to a compact higher order stature forming the dense arrays of
nucleosomes seen in heterochromatin regions (Figure 4).
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Figure 4. Schematic illustration of histone modification mechanisms mediated by vitamin D3 and
the link to basal transcription machinery. The DNA is packaged within the eukaryotic cell leading to
a compact higher order stature forming the dense arrays of nucleosomes seen in heterochromatin regions.
Since the chromatin is tightly packed, the chromatin is in-accessible to transcription factors. The direct
protein-protein interaction with co-activators which have HAT activity leads to local chromatin opening.
Two major epigenetic mechanisms facilitates relaxation of chromatin structure and promotes gene
expression; mainly DNA methylation and Histone protein modifications. (a) DNA methylation in the
promoter region of VDR gene results in the inactivation and lack of VDR gene expression. (b) When
HDAC-corepressor complexes are bound to the heterochromatin region, the transcriptional machinery
is repressed resulting in downstream gene silencing. (c) When VDR-RXR complex is bound to HATs,
HAT transfers acetyl group to histones leading to histone acetylation and chromatin remodelling.
The chromatin machinery is then relaxed resulting in binding of TFs and activation of expression of
downstream genes. Abbreviations: HAT, Histone Acetyl Transferase; HDAC, Histone deacetylase;
RXR, Retinoid X Receptor; VDR, Vitamin D Receptor; VDRE, Vitamin D Response Elements.
Despite being tightly packed, the chromatin is accessible to transcription factors due to the two
major epigenetic mechanisms involved in the process; mainly Histone protein modifications and DNA
methylation. Epigenetic signatures can thus be highly dynamic and lead to short-lived stages such as
response of chromatin to stress signals [125]. Studies assessing the role of epigenetic mechanism in
PAD formation is scarce [126,127]. Recently, we have shown that epigenetic silencing mechanisms
results in AAA formation in human and in mice [128,129] indicating the importance of epigenetic
mechanisms in disease formation.
5.1. Histone Modifications
Histone proteins are bound to the DNA and post-translational modifications of the N-terminal tails
of histone proteins allow the chromatin to relax, and genes to become activated. Histone modifications
change in response to environmental stimuli [130]. Histones are major protein components of chromatin
that undergo post-translational modifications, including acetylation of lysines, methylation of lysines
and arginines, and phosphorylation of serine and threonine residues [131]. Histone acetylation
generally correlates with transcriptional activation and is dependent on a dynamic interaction between
histone acetyltransferases (HATs) and histone deacetylases (HDACs) [132].
Primary epigenetic effects of vitamin D are linked to promoting chromatin accessibility through
histone modifications, mainly acetylation. Interaction with chromatin and its modifying enzymes
is a central element in 1α,25(OH)2D3 signalling [133]. Vitamin D binds through the VDR to the
VDRE, which results in transcriptional regulation through epigenetic mechanisms such as histone
modification, chromatin remodelling and altered binding of RNA polymerase II [134,135] (Figure 4).
For example, treatment of THP-1 cells with 1,25-D3 increased acetylation of histone protein (H3K27ac)
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at the promoter of several early VDR target genes [136]. Higher levels of histone acetylation were also
found at specific regions in VDR and 1,25 (OH)2D3-induced binding of VDR to these specific sites
was also associated with increased histone levels [137] (Figure 4). Furthermore, VDR reactivation
induced by the HDAC inhibitor Trichostatin-A along with calcitrol was found to upregulate a group
of repressed VDR gene targets controlling proliferation and induction [138,139]. It was also found
that in the absence of ligand, VDR is able to bind to genomic DNA [140] and forms complexes with
co-repressor proteins and HDACs [141]. Furthermore, the VDR-RXR dimer interacts with HATs to
induce transcriptional activation [142].
Studies directly assessing histone modifications in PAD are meagre, however there is plenty
of evidence in the literature which shows a strong effect of histone modification in mechanisms
underlying PAD formation [126,143]. Most of the vitamin D responsive chromatic sites cluster at
specific loci within the human genome and the most prominent of the region is on chromosome 6 which
harbours the human Leukocyte antigen (HLA) region. This is significant as the HLA cluster is also
a region important for vitamin D responsiveness to epigenome shows the strong immune regulation
potential of vitamin D [144]. Studies shows that the primary activation step after 1α,25(OH)2D3-VDR
complex is the transient opening or closing of the chromatin at specific enhancer and TSS with RNA
polymerase II and other nuclear adaptor proteins, which determines the regulation (activation or
suppression) of primary vitamin D target genes [145] (Figure 4). Nuclear Receptor Corepressor 1
(NCOR1) is a co-repressor that contains nuclear receptor interacting domains and interacts with various
nuclear receptors, including VDR [146]. NCOR1 recruits histone deacetylase enzymes (HDACs) which
deacetylase histone-tails and thereby condense the DNA structure and prevent gene-transcription.
1,25(OH)2D3 has been shown to increase NCOR1 gene expression [147] showing a direct epigenomic
regulation role.
Two months of daily supplementation of vitamin D3 (10 µg/50 µg) resulted in significant regulation
of 291 genes and weekly supplementation using a higher dose (500 µg) over 35–years resulted in
significant changes in 99 genes in PBMNCs compared to placebo group [148]. The Phase I of the
VitDbol vitamin D intervention trials [149] showed that a single bolus of vitamin D3 (2000 µg) results in
a change in chromatin assembly in a selected genomic region [150]. This leads to a further proof of
principle study during Phase II where one individual was exposed to vitamin D3 bolus for 3 consecutive
days for every 28 days [149,150]. Time-point analysis of epigenome wide chromatin accessibility
was assessed by applying a technique called formaldehyde assisted isolation of regulatory elements
sequencing (FAIRE-seq). Results shows that under in vivo conditions, even a minor rise in serum
levels of 1α,25(OH)2D3 is sufficient to result in significant changes at hundreds of sites within the
epigenome of human leukocytes. The Phase II of VitDbol study conducted an RNA sequencing
(RNA-seq) for the transcriptome-wide analysis of the effects of a vitamin D3 bolus on PBMCs from
5 individuals [151]. It was shown that 702 genes were being significantly modulated by vitamin D.
This observation is supported by an elegant in vitro cell culture study that shows convincing evidence
that the 1α,25(OH)2D3 significantly affect thousands of human genomic loci, promoting in major
changes in the epigenome [152].
5.2. DNA Methylation
Alterations in DNA methylation lead to aberrant gene expression and disruptions of genomic
integrity, which contribute to development and progression of PAD and vitamin D can regulate these
processes. Recent research suggests the potential of vitamin D to modulate the gene expression through
modulating the epigenetic marks [153]. Previous reports show that concentrations of 1,25(OH)2D3
in serum vary widely in individuals based on variations in diet, sun exposure, difference in age,
adiposity and genetic and epigenetic variations [154–156]. Vitamin D regulates expression of genes in
genome wide scale as evidenced by the activation of more than 200 genes in lymphoblasts stimulated by
calcitriol [134]. Previous population-based cohort studies identifies different gene expression profiles
in individuals with different concentrations of plasma 25(OH)D [157]. Primary human PBMNCs
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subjected to calcitriol (100–120 nM) exposure showed altered expression of known vitamin D responsive
genes [158]. In healthy subjects global, age-related methylation of human rectal mucosa was influenced
not only by gender, folate availability, and selenium, but also by vitamin D status [159].
Interestingly, a weak positive correlation was observed between vitamin D level with methylation
of LINE-1 (genomic long interspersed nuclear element-1), a mammalian autonomous retrotransposon,
and increasing stability of this region [159]. A recent study associated severe vitamin D deficiency with
methylation changes in leukocyte DNA, although the observed differences were relatively small [160].
This study suggested that subjects with vitamin D deficiency were more likely to show reduced
synthesis and increased catabolism of active vitamin D. Whether this was the cause of the vitamin D
deficiency or the consequence thereof is not clear and needs further studies. Furthermore, analysis of
genome-scale methylation in leukocytes from vitamin D (plasma 25(OH)D) deficient adolescents in
comparison to adolescents with sufficient circulating plasma 25(OH)D, showed several gene loci to be
differentially methylated [160].
Vitamin D metabolism and DNA methylation may have a complex relationship [161].
Previous studies have shown that vitamin D signalling is controlled by epigenetic mechanisms,
and stimulation using vitamin D influences global methylation markers [159]. Previous reports show
that the major regulators of 1,25-D3 levels and “the vitamin D tool” genes signalling through CYP2R1,
CYP24A1, CYP27B1, and VDR, are prone to epigenetic regulation [153]. For example, the tissue levels
of the biologically active form of vitamin D (1,25(OH)2D3) is controlled though its biosynthesis by
α–hydroxylase or CYP27B1. The 24-hydroxylase enzyme encoded by the CYP27B1 gene is the main
player in the catabolism of calciferol to less active vitamin D metabolites and previous studies shows
that the CYP27B1 gene expression is epigenetically modulated in various mammalian tissues [162,163].
CYP2R1, CYP24A1 and VDR have CpG islands in their respective promoter regions and CYP27B1
has a CpG island located in the gene body [153,164]. Hypermethylation of VDR promoter region
generally influences VDR expression and function suggesting the crucial role of epigenetics in vitamin
D signalling [165].
Altered DNA methylation has also been implicated in Vitamin D mediated regulation of expression
of a number of genes [166–168]. For example, high dietary vitamin D intake was associated with lower
methylation of the two Wnt antagonists Dickkopf 1 (DKK1) and WNT5A [168]. The altered expression
of the gene in the vitamin D downstream signalling pathway such as Wnt/β-catenin pathway will
be crucial in AAA. Wnt inhibitor Sclerostin was recently reported to undergo DNA methylation in
AAA [128]. Similarly, our recent report shows that in humans, serum angiotensin converting enzyme
(ACE)-2 activity was negatively associated with AAA diagnosis [129]. Furthermore, the expression
of ACE-2 was lower in infra-renal biopsies of patients with AAA than organ donors due to dense
methylation in the promoter region of ACE-2 gene. The neural precursor cells expressed a ubiquitin
ligases, the Developmentally down-regulated protein-4 (NEDD4) which function in the ubiquitin
proteasome system of protein degradation. Nedd4 deletion in mice results in deformed aortic structures
with disarranged elastin fibres and vitamin D was shown to induce aorta calcification in these mice
even at very low levels [169]. Furthermore, epigenetic analysis revealed that methylation levels of
human NEDD4 gene promoter were significantly increased in atherosclerosis patients suggesting that
vitamin D supplementation might not be a possibility in all atherosclerotic diseases.
A 12-month interventional study in elderly people showed that intervention with a combination
of vitamins (combination of vitamin D, B, and Calcium) differentially affected surrogate markers
of epigenetic age, mainly CpG methylation of three age associated genes (Aspartoacylase, ASPA;
cAMP-specific 3′,5′-cyclic phosphodiesterase 4C, PDE4C and integrin alpha-IIb, ITGA2B) compared
with vitamin D + Calcium alone [170]. This study suggest that people can have higher biological age
than chronological age, which might be due to accelerated aging as a result of hypovitaminosis. This is
an important observation as accelerated senescence of cells is a crucial underlying pathological change
occurring in age-associated diseases such as AAA.
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6. Future Direction
Vitamin D insufficiency has emerged as a public health issue in industrialised societies worldwide.
Maintaining an optimal vitamin D serum level seems important not only for calcium homeostasis but
also for minimising cardiovascular risk, blood pressure control, metabolic syndrome, prevalence of
stroke, and PAD. The observational data support the strong link between epigenetic effects of vitamin
D status and PAD formation. However, there is still a lack of clarity regarding the ideal threshold of
vitamin D that is required to prevent PAD. However, consuming higher amounts of vitamin D may
interfere with regulation of phosphate metabolism through Klotho gene product and fibroblast growth
factor, which has detrimental consequences including aortic calcification [171]. It is therefore important
that the ideal level of vitamin D is identified that can reduce the risk of PAD development while not
having other deleterious effects associated with high doses.
There is strong evidence presented in this review, which suggests that the vitamin D system and
epigenetic mechanisms are closely connected. The vitamin D system is shown to regulate various
epigenetic mechanisms and also vitamin D system itself is regulated by those mechanisms. As it
has been shown by multiple studies, the regulation of epigenetic mechanisms is finely tuned and
any slight de-regulation can lead to pathological conditions due to its numerous roles in critical
pathological systems.
Considering the modern lifestyle of the increasing global aging population and indoor-oriented
sedentary lifestyle, the epigenetic effects of vitamin D in promoting PAD is highly important for public
health. Since the epigenome can be modified, consuming sufficient micronutrients including vitamin
D may be an alternative method of prevention of any disease. Identifying the molecular mechanisms,
the effect of vitamin D insufficiency and the link to PAD formation will unveil new therapeutic avenues
and targets. The emerging field of nutri-genomics and nutri-epigenetics will pave way to identify
and treat the PAD triggers early and also provide sustainable solutions to protect the arteries from
developing occlusive disease. Even though there is evidence of vitamin D levels in PAD formation,
the beneficial role of vitamin D supplementation still remains inconclusive and needs further research.
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Abbreviation
AAA Abdominal aortic aneurysm
AngII Angiotensin II
ARIC Atherosclerosis Risk In Communities
CLI Critical limb ischemia
CVD Cardio vascular disease
DBP Vitamin D binding protein
EC Endothelial cell
ECM Extracellular matrix
eNOS Endothelial nitric oxide synthase
EPC Endothelial progenitor cell
HAT Histone acetyl transferase
HDAC Histone deacetylase
IC Intermittent claudication
MMP Matrix metalloproteinase
NO Nitric oxide
(OH)D Hydroxyvitamin D
PAD Peripheral arterial disease
PAOD Peripheral arterial occlusive disease
PBMNC Peripheral blood mononuclear cells
RAAS Renin-angiotensin-aldosterone system
RXR Retinoid X receptor
TSS Transcription start site
VDR Vitamin D receptor
VSMC Vascular smooth muscle cell
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